Health Advisory: Pause in administration of the Johnson & Johnson COVID-19 vaccine; Reporting of cases of thrombosis with thrombocytopenia syndrome (TTS) after receipt of Johnson & Johnson vaccine

April 21, 2021

Clinicians are currently recommended to pause the use of the Johnson & Johnson (J &J) COVID-19 vaccine (Janssen) until the CDC’s Advisory Committee on Immunization Practices (ACIP) is able to further review rare cases of cerebral venous sinus thrombosis with thrombocytopenia occurring in individuals after receiving the vaccine. The ACIP will meet on Friday, April 23 regarding the J & J COVID-19 vaccine.

All cases of thrombosis with thrombocytopenia syndrome (TTS) following receipt of J & J COVID-19 vaccine, as well as other adverse events following vaccination, should be reported to the CDC/FDA Vaccine Adverse Event Reporting System (VAERS). The FDA Emergency Use Authorizations for the COVID-19 vaccines require reporting of severe vaccine-associated adverse events to VAERS.

On April 16, the American Society of Hematology (ASH) released guidance for diagnosis and clinical management.

In addition to promptly submitting a VAERS report, CDPH requests that all providers notify their Local Health Departments (LHDs) within one day regarding cases of TTS following receipt of J & J COVID-19 vaccine. Providers should make notifications by phone (or in another manner if requested by the LHD). The LHD will request a copy of the VAERS report and the VAERS report number. (When submitting a VAERS report, the report can be previewed and printed to PDF so that the submitter can retain a copy. The submitter can also request to have the VAERS report number emailed to them.)

Resources
HHS: VAERS Reporting Portal
HHS: VAERS Overview
CDC: Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States
American Society of Hematology (ASH): Clinical Guidance
Brighton Collaboration: Case-Finding Definition of Thrombosis with Thrombocytopenia Syndrome